Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 3.6/5
Akeso Biopharma Inc (9926 HK)
Watchlist
Contact IR
217
Analysis
Health Care
•
China
Akeso Inc. operates operatesa s a biotech company. The compnay develops treatments and therapies for various types of diseases. Akeso serves cutomers worldwide
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Akeso Biopharma Inc
•
02 Dec 2024 00:55
2025 High Conviction – China Healthcare: Chinese Biotech to Compete on the International Stage
Akeso's investment certainty increases based on promising HARMONi-2 data, leading to potential market value surpassing Innovent and reaching above...
Xinyao (Criss) Wang
Follow
448 Views
Share
bullish
•
Akeso Biopharma Inc
•
14 Oct 2024 00:55
Akeso Biopharma Placement - The Placing Price Is Not Cheap Despite Positive Business Progress
Akeso delivers impressive HARMONi-2 data, which greatly increases the possibility of positive OS. But the market cap already partially reflects...
Xinyao (Criss) Wang
Follow
515 Views
Share
bullish
•
Akeso Biopharma Inc
•
10 Oct 2024 11:38
Akeso Placement - Opportunistic Raise, past Deal Record Has Been Mixed but Relative Size Is Small
Akeso Biopharma Inc (9926 HK) is looking to raise around US$200m from its primary placement. Proceeds from the placement will be used for R&D.
Sumeet Singh
Follow
528 Views
Share
bullish
•
Akeso Biopharma Inc
•
11 Sep 2024 00:55
Akeso Biopharma Inc (9926 HK) - Something Beautiful Is Happening
AK112's HARMONi-2 results show promise, but FDA approval depends on OS. Summit is actually a better investment than Akeso. Investors bet Summit to...
Xinyao (Criss) Wang
Follow
383 Views
Share
bullish
•
Akeso Biopharma Inc
•
03 Sep 2024 10:46
[Akeso Inc. (9926 HK, BUY, TP HK$63) TP Change]: Too Many Positives to Count…Reiterate TOP BUY
Akeso reports better-than-expected financial results, with positive Phase III start for CD-47 mAb (AK117) leading to a raised price target and top...
Blue Lotus Research Institute
Follow
268 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.50.0
x